[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-of-pancreas\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-of-pancreas":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,78,158,182,205,238,259],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100326955","tumour-regulatory-molecules-in-early-pancreatic-cancer-detection-100326955",false,"NCT03536793","Tumour Regulatory Molecules in Early Pancreatic Cancer Detection","Study of Tumour Regulatory Molecules as Markers of Malignancy in Pancreatic Cystic Lesions","TEM-PAC","Inclusion Criteria:\n\nGeneral\n\n* Capable of giving written informed consent\n* Age ≥18 years\n\nPancreatic Cancer Cohort\n\n\\- Diagnosed with localised pancreatic cancer amenable to resection (distal pancreatectomy, total pancreatectomy or Whipple's procedure).\n\nOR - Diagnosed with inoperable localised pancreatic cancer and referred for further management (malignant control subgroup).\n\nPancreatic Cysts Cohort\n\n\\- Presence of cystic lesions where MDT have agreed further diagnostic intervention procedures (including FNA\u002FEUS) necessary.\n\nOR - Patient the MDT have agreed have resectable lesions suspicious for pancreatic malignancy and going to surgery.\n\nBenign Cohort\n\n\\- Referral for endoscopic cystogastrostomy for complicated acute pancreatitis characterised by peripancreatic fluid collections and pseudocysts in development or matured (non-resolving and requiring further intervention).\n\nOR\n\n* Referral for cholecystectomy for cholocystitis\u002Fchololethiasis. OR\n* Patient planned to have endoscopy investigation for dyspepsia (normal control subgroup).\n\nExclusion Criteria:\n\nGeneral\n\n* Inability to provide written informed consent\n* Other known malignant condition, either active or in complete remission ≤5 years\n* HIV, hepatitis C, or any other known communicable disease",true,"ALL","18 Years",{"count":21,"type":22},180,"ESTIMATED","OBSERVATIONAL","The effective diagnosis of pancreatic cancer is often quite challenging, due to a lack of disease-specific symptoms, resulting in the majority of patients presenting with advanced disease, with an associated dismal prognosis. Earlier detection of pancreatic cancer, at a stage where surgery is feasible, would greatly increase the 5-year survival rate. Detecting pancreatic cancer early is therefore vital to improve the prognosis for these patients.\n\nPre-cancerous pancreatic cysts are an early indicator of malignant transformation. The ideal screening test would be capable of detecting pancreatic cancer at these initial stages. Current procedures for pancreatic cancer diagnosis are invasive, uncomfortable and costly, and can be considered unnecessary in those cysts found to be benign.\n\nWe propose to study a number of tumour regulatory molecules that have been the subject of research in laboratories at the University of Hull (e.g., tissue factor (TF), adrenomedullin (AM) using enzyme-linked immunosorbent assays (ELISA) tests) that have been studied in the context of carcinogenic transformation in more common malignancies but have yet to be fully tested in pancreatic malignant transformation. The recent introduction of platform technologies at the University of Hull has broadened this area of investigation by giving us access to next generation genomic sequencing and proteomic analyses of small amounts of tissue samples. We intend to analyse pancreatic cystic fluid samples using these technologies to discover new regulatory molecules.\n\nAltogether, his study will measure the levels of novel regulatory molecules and genetic changes involved with pancreatic cancer carcinogenesis using a combination of conventional techniques (e.g. ELISA) and state-of-the-art platform technologies in pancreatic cysts from those patients in whom cancer may be suspected, to determine the potential of these molecules to serve as markers to detect early changes towards pancreatic cancer.",[26,27],"Cancer of Pancreas","Pancreas Cyst",[29],"Early detection of pancreatic cancer","RECRUITING","2026-06-22",{"date":33,"type":34},"2026-06-23","ACTUAL",{"date":36,"type":34},"2018-10-24",{"date":38,"type":22},"2029-02-28",{"name":40,"class":41},"Hull University Teaching Hospitals NHS Trust","OTHER_GOV",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":64,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":42},"100360753","phase-2-tumor-subtypes-in-subjects-on-folfirinox-with-non-metastatic-pancreatic-cancer-100360753","NCT03977233","Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer","Inclusion Criteria:\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n* Histologically or cytologically confirmed adenocarcinoma of the pancreas with no evidence of distant metastatic disease.\n* Subject has no evidence of co-morbidities precluding the potential to undergo surgical resection of PDAC as determined by surgical investigator.\n* Subjects must be willing to undergo a mandatory pre- and post-treatment EUS guided core biopsy of the pancreatic mass.\n* Measurable or non-measurable but evaluable (as determined by Response Evaluation Criteria in Solid Tumors version 1.1 \\[RECIST 1.1\\]) resectable, borderline resectable or unresectable locally advanced PDAC.\n* Subject has adequate performance status as defined by ECOG performance status 0 or 1.\n* Subject has received no prior chemotherapy or chemoradiotherapy for pancreatic cancer. Subjects have not previously received surgery to remove pancreatic cancer.\n* Age ≥ 18 years of age.\n* Subject has adequate organ function at study entry.\n* Subject has life expectancy of at least 6 months.\n\nExclusion Criteria:\n\n* Subject has any evidence of local recurrence or metastatic pancreatic cancer.\n* Other malignancies within the past 5 years except for adequately treated cervical or vulvar carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1).\n* Subject has hypersensitivity to 5FU, oxaliplatin or other platinum agent, or irinotecan or to their excipients.\n* Subject has known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency.\n* Participation in any investigational drug study within 4 weeks preceding the start of study treatment. Subjects are not permitted to participate in another investigational drug study while being treated on this protocol. Subjects participating in other clinical trials that are receiving SOC FOLFIRINOX are permitted on study.\n* Subject has current evidence of any condition that makes participating in this study not in the best interest of the subject, including but not limited to:\n\n  * Myocardial infarction within the past 6 months\n  * New York Heart Association (NYHA) Class III or IV heart disease\n  * Active infection requiring IV antibiotics\n* Subject has a history of or suspected Gilbert's syndrome or known homozygosity for UGT1A1\\*28 polymorphism (baseline testing not required).\n* Subject has sensory peripheral neuropathy grade ≥ 2.\n* Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.\n* Subject is unable or unwilling to discontinue use of ketoconazole or St John's wort. Use of phenytoin, carbamazepine, phenobarbital, rifampin and rifabutin is discouraged, but not contraindicated. If subjects require phenytoin, carbamazepine or phenobarbital monitoring of drug levels is suggested during the study.\n* Subject is pregnant or lactating.\n* Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial.","99 Years",{"count":52,"type":22},45,"INTERVENTIONAL",[55],"PHASE2","This is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before surgery to remove the tumor. Certain types of PDAC tumors can be surgically resected (removed). However, not all types of PDACs are resectable, especially if they are close to important structures like blood vessels or intestines. These types of PDACs are treated with chemotherapy such as FOLFIRINOX. Research studies showed that chemotherapy after surgical resection of PDAC tumors reduced the risk of the cancer returning.\n\nChemotherapy is used to treat PDAC that has not spread outside of the pancreas and is not resectable. FOLFIRINOX is a chemotherapy treatment that combines multiple chemotherapeutic agents, including oxaliplatin, leucovorin, irinotecan, and 5-FU. Patients receive these agents by intravenous infusion. Of these drugs, 5-FU requires you to return home with a chemotherapy pump that will deliver chemotherapy over 46 hours. This regimen has been studied in pancreatic cancer that has been removed with surgery as a method for preventing the cancer from returning. Studies showed FOLFIRINOX chemotherapy reduced the risk of cancer returning and increased patients survival. In this study, researchers want to know if FOLFIRINOX chemotherapy given before surgery will make the cancer easier to remove with surgery and increase the chances of the cancer staying away after surgery.\n\nResearchers have shown that pancreatic cancers are not all the same when you look at the DNA and RNA that is inside a pancreatic cancer cell.\n\nDepending on the expression of different genes in a cancer cell, some pancreatic cancers may respond differently to chemotherapy. In this study researchers want to know if FOLFIRINOX chemotherapy can change the genetic profile of the cancer. This will be studied by obtaining a biopsy of the cancer before the start of chemotherapy, and after 8 treatments of chemotherapy. They will also study cancer cells that will be collected from blood samples.",[58,26,59,60,61,62,63],"Pancreatic Ductal Adenocarcinoma (PDAC)","Pancreatic Cancer, Adult","Pancreas Adenocarcinoma","Pancreatic Neoplasms","Pancreatic Cancer Non-resectable","Pancreatic Cancer Resectable",[65,62,63,66,67,59],"Pancreatic Ductal Adenocarcinoma","neoadjuvant FOLFIRNOX","FOLFIRINOX","2026-01-09",{"date":70,"type":34},"2026-01-13",{"date":72,"type":34},"2019-06-12",{"date":74,"type":22},"2030-01",{"name":76,"class":77},"UNC Lineberger Comprehensive Cancer Center","OTHER",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":84,"targetDuration":86,"studyType":23,"phases":4,"briefSummary":87,"conditions":88,"keywords":131,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":157},"100320510","synergy-ai-artificial-intelligence-based-precision-oncology-clinical-trial-matching-and-registry-100320510","NCT03452774","SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","Inclusion Criteria:\n\n* Pts with solid and hematological malignancies;\n* Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2\u002FNeu, Tumor mutational burden\u002Fload (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A\u002FB, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1\u002F2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA\u002FB\u002FC, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.\n\nThese biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform\n\n* Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and\u002For patient\n\nExclusion Criteria:\n\n* ECOG PS \\> 2;\n* Abnormal organ function;\n* Hospice enrollment",{"count":85,"type":22},50000,"36 Months","International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.",[89,90,26,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130],"Cancer, Metastatic","Cancer","Cancer of Liver","Cancer of Stomach","Cancer Liver","Cancer of Rectum","Cancer of Kidney","Cancer of Esophagus","Cancer of Cervix","Cancer of Colon","Cancer of Larynx","Cancer, Lung","Cancer, Breast","Cancer, Advanced","Cancer Prostate","Cancer of Neck","Cancer of Skin","Neuroendocrine Tumors","Carcinoma","Mismatch Repair Deficiency","BRCA Gene Rearrangement","Non Hodgkin Lymphoma","Leukemia","Non Small Cell Lung Cancer","Cholangiocarcinoma","Glioblastoma","Central Nervous System Tumor","Melanoma","Urothelial Carcinoma","Bladder Cancer","Ovarian Cancer","Endometrial Cancer","Testicular Cancer","Breast Cancer","COVID","Myelofibrosis","Myeloproliferative Neoplasm","Myeloproliferative Disorders","Follicular Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Myelodysplastic Syndromes",[132,133,134,135,136,137,138,139,140,141,142,143,144,145,146],"artificial intelligence","virtual tumor board","clinical trial","clinical trial matching","electronic medical record","machine learning","cost of care","targeted therapy","immunotherapy","precision medicine","precision oncology","cancer","value based care","real world data","data analytics","2025-10-25",{"date":149,"type":34},"2025-10-28",{"date":151,"type":34},"2018-01-01",{"date":153,"type":22},"2040-06",{"name":155,"class":156},"Massive Bio, Inc.","INDUSTRY",68,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":53,"phases":168,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":42},"100519687","efficacy-of-first-line-gemcitabine-chemotherapy-in-gemcore-metastatic-pancreatic-adenocarcinoma-patients-100519687","NCT06046794","Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients","Phase IV Study Assessing Efficacy of First-Line Chemotherapy With Gemcitabine in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients Ineligible to FOLFIRINOX Treatment","GemSign-01","Inclusion Criteria:\n\n* Metastatic pancreatic adenocarcinoma histological proved\n* FOLFIRINOX chemotherapy-ineligible patient and going to receive first-line metastatic chemotherapy with gemcitabine monotherapy\n* Tumor material allowing assessment of GEMCore status (i.e. FFPE block with tumor cellularity ≥ 10%);\n* Life expectancy \\> 2 months;\n* Measurable target according to RECIST 1.1 criteria;\n* No previous treatment in metastatic situation;\n* Age ≥ 18 years;\n* Patient not opposed to study participation;\n* Affiliation to a social security system, or beneficiary of such a scheme.\n\nExclusion Criteria:\n\n* Contraindication to Gemcitabine treatment;\n* ECOG performance status ≥ 3;\n* Person in emergency situation or unable to express non-opposition;\n* Patient under a legal protection measure (adult under guardianship, curatorship or safeguard of justice);\n* Unable to undergo medical follow-up for geographical, social or psychological reasons.",{"count":167,"type":22},100,[169],"NA","The goal of this interventional study is to learn about the efficacy of first-line chemotherapy with Gemcitabine in metastatic pancreatic adenocarcinoma patients expressing the GemCore signature in their tumor. The main question it aims to answer is to assess efficacy of Gemcitabine (tumor response, survival rate) in the population of patient bearing the GemCore signature.\n\nParticipants will start the chemotherapy with Gemcitabine as usually performed in standard care of their center. They will consent to a genomic analyze of their tumor to know if it bears the GemCore signature. The center will manage the participant's follow up as usually realized in standard care.",[172],"Cancer Of Pancreas","2025-06-10",{"date":175,"type":34},"2025-06-11",{"date":177,"type":34},"2024-05-23",{"date":179,"type":22},"2027-11-01",{"name":181,"class":77},"Institut Paoli-Calmettes",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":189,"targetDuration":191,"studyType":23,"phases":4,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":42},"100542564","iconographic-registry-of-pancreatobiliary-endoscopy-procedures-100542564","NCT06344507","Iconographic Registry of Pancreatobiliary Endoscopy Procedures","TAILOR-EUS","Inclusion Criteria:\n\n* Suspected or confirmed diagnosis of inflammatory pancreatic disease (e.g., acute, recurrent, or chronic pancreatitis) or autoimmune bilio-pancreatic disease (e.g., autoimmune pancreatitis) or bilio-pancreatic neoplastic disease, necessitating an endoscopic ultrasonography procedure.\n* Age over 18 years.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Pregnancy and breastfeeding status.\n* Contraindications to the endoscopic ultrasonography procedure",{"count":190,"type":22},12000,"1 Day","The aim of the TAILOR-EUS study (Iconographic Registry of Bilio-Pancreatic Endoscopic Ultrasound Procedures) is to establish a clinical registry comprising images and videos generated during endoscopic procedures conducted for the investigation of pancreatic diseases (PD). The study will compile historical, pathological, and imaging data from approximately 12,000 patients (2,000 retrospectively and 10,000 prospectively) who underwent endoscopic ultrasound procedures for inflammatory pancreatic conditions (e.g., acute, recurrent, chronic pancreatitis), autoimmune bilio-pancreatic diseases (e.g., autoimmune pancreatitis), neoplastic bilio-pancreatic conditions, and screenings for individuals at high risk of developing such diseases at the Bilio-Pancreatic Endoscopy and Endoscopic Ultrasound Unit of the IRCCS San Raffaele Hospital between 2000 and 2027.\n\nParticipants have undergone or will undergo the standard diagnostic pathway appropriate for their conditions as part of routine clinical practice. All instrumental examinations and endoscopic ultrasound procedures are integral to the standard diagnostic and therapeutic approach for pancreatic diseases.",[194,26,195,106],"Pancreas Neoplasm","Pancreatitis","2025-04-30",{"date":198,"type":34},"2025-05-02",{"date":200,"type":34},"2022-03-28",{"date":202,"type":22},"2027-12-31",{"name":204,"class":77},"IRCCS San Raffaele",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":53,"phases":215,"briefSummary":216,"conditions":217,"keywords":218,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":42},"100442434","wet-heparinized-suction-for-abdominal-cancer-100442434","NCT05041335","Wet Heparinized Suction for Abdominal Cancer","Wet Heparinized Suction: A Novel Technique to Enhance Tissue Acquisition for Endoscopic Ultrasound Guided Fine Needle Biopsy (EUS-FNB) of Solid Abdominal Masses: A Randomized Prospective Trial","EUS Heparin","Inclusion Criteria:\n\n* Age ≥ 18 year\n* Non-pregnant Patients\n* Patients with the presence of a solid abdominal mass as seen on diagnostic imaging \\[ie. ultrasound (US), computer tomography (CT) or magnetic resonance imaging (MRI)\\] scheduled to undergo EUS examination OR Patients who underwent a prior EUS-FNA\u002FFNB for solid pancreatic mass and did not receive a conclusive diagnosis\n* Patients with platelet count \\> 50,000\n* Patients with International Normalized Ratio (INR) \\\u003C 1.5\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnant Patients\n* Patients who cannot consent for themselves\n* Patients with anticoagulants or anti-platelet agents (excluding aspirin) within the last 7-10 days\n* Patients with cystic abdominal masses\n* Patients with a platelet count \\\u003C 50,000\n* Patients with an INR \\> 1.5\n* Patients with a heparin or porcine allergy\n* Patients with prior heparin induced thrombocytopenia (HIT)\n* Patient's with religious aversion to porcine-containing products",{"count":214,"type":22},42,[169],"The purpose of this research is to compare the amount and quality of tissue obtained by EUS-FNB when the device is flushed with an anticoagulant or \"blood thinner\" vs. saline a salt water solution as well as the use of a microsieve in order for the doctor to look at the tissue to check the acceptability of the specimens before sending for analysis.\n\nYou will be randomly assigned (like a flip of a coin) to have either the blood thinner or the salt water solution placed within the needle being used to sample your abdominal tumor and to have either a sieve used or not.\n\nYou will be one of 42 participants enrolled in this data collection study which includes 1 sites in the United States.",[26,92,96,91,90],[143,219,220,221,222,223,224,225,226,227],"esophagus","stomach","gastric","pancreas","biliary","bile","bile duct","liver","hepatic","NOT_YET_RECRUITING","2025-04-21",{"date":231,"type":34},"2025-04-22",{"date":233,"type":22},"2026-03-15",{"date":235,"type":22},"2027-01-12",{"name":237,"class":77},"H. Lee Moffitt Cancer Center and Research Institute",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":247,"conditions":248,"keywords":249,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":42},"100527479","cell-free-dna-chromatin-immunoprecipitation-chip-for-diagnosing-cancer-100527479","NCT06148298","Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer","Cell-free Chromatin Immunoprecipitation (CfChIP) from Blood Plasma As a Diagnostic and Prognostic Tool in Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\n* 18 years old or older\n* Pancreatic cancer patients\n\nExclusion Criteria:\n\n* Children may not register\n* Persons who are unable to consent may not register",{"count":246,"type":22},24,"The goal of this research is to use chromatin immunoprecipitation, a method used to study protein-DNA interaction, as a tool to diagnose and prognose pancreatic ductal adenocarcinoma in human samples.\n\nThis is a Non-Human Subject Research study. All participants are de-identified.",[26],[143,222],"2024-12-03",{"date":252,"type":34},"2024-12-06",{"date":254,"type":34},"2023-05-24",{"date":256,"type":22},"2025-05",{"name":258,"class":77},"University of Central Florida",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":53,"phases":268,"briefSummary":270,"conditions":271,"keywords":275,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":4},"100467069","phase-1-study-to-assess-the-safety-and-preliminary-efficacy-of-sti-1386-oncolytic-virus-in-relapsed-or-refractory-solid-tumors-100467069","NCT05361954","Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors","A Phase 1b, Dose-Escalation Study of the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Patients With Relapsed or Refractory Solid Tumors","Inclusion Criteria:\n\n* Histologically confirmed extracranial solid tumors that are relapsing or refractory including locally advanced pancreatic cancer, unresectable soft tissue sarcomas, hepatic metastases due to colorectal cancer\n* At least one measurable disease per Response Evaluation Criteria in Solid Tumors v. 1.1 (RECIST 1.1) with a non-nodal lesion with longest diameter ≥ 10 mm or nodal lesions with short diameter ≥ 15 mm\n* Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2\n* As assessed by the investigator, ≥ 3 month life expectancy\n* Adequate hematologic, liver and renal function at Screening as determined by lab criteria\n* Recovered \\\u003C Grade 2 from all acute toxicities from previous therapy\n* Has not had prior treatment with high dose corticosteroids within the 2 weeks of screening\n* Is willing and able to comply with the study schedule and other protocol requirements\n* Willing to follow contraception guidelines\n\nExclusion Criteria:\n\n* Have a primary brain tumor\n* Use of an investigational drug or local therapy or agent within 2 weeks of first dose of study drug. Current systemic chemotherapy per investigator's discretion is allowed, but no immune checkpoint inhibitors or immune modulators\n* Use of anticoagulants or anti-platelet agents unless subject can safely start\u002Fstop to allow intratumoral injections\n* Use of bevacizumab (Avastin) within 28 days of the STI-1386 injection\n* Diagnosis of other malignancies that have required therapy in the last year or are not in complete remission. Exceptions include non-metastatic basal cell or squamous cell carcinomas of the skin, prostate cancer or cancer in situ that does not require treatment currently or is otherwise under control\n* Requiring chronic systemic immunosuppressants, including steroids \\> 20 mg\u002Fday\n* Presence of bulky disease defined as any single mass \\> 5 cm in greatest dimension will trigger a discussion to determine eligibility\n* New York Heart Association (NYHA) Class \\>3 of left ventricular ejection fraction (LVEF) \\\u003C 50%\n* Prolonged corrected QT interval as determined by 12-lead electrocardiogram\n* Has spinal cord compression or clinically unstable brain metastases within 4 weeks of first dose of study drug\n* Evidence of active herpes infection and\u002For chronic herpes infection requiring prophylactic antiviral medication that may not be discontinued\n* Has an active or recent COVID-19 infection, must have a negative RT-PCR test and not have had symptoms within 4 weeks of day 1 of study drug administration\n* Any active infection requiring systemic therapy within 72 hours of injection of STI-1386, excluding anti-viral maintenance therapy for HIV\n* Moderate to severe chronic obstructive pulmonary disease or other moderate to severe chronic respiratory conditions unless under treatment and stable for the 3 months of screening\n* Have active human immunodeficiency virus (HIV) infection, human T-cell leukemia virus type 1 (HTLV1) infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia\n* Pregnant or lactating or up to 3 months post last dose\n* Underlying medical conditions that, in the opinion of the investigator and\u002For medical monitor will prevent the subject from participating\n* Allergy to acyclovir and related anti-HSV antiviral agents",{"count":267,"type":22},36,[269],"PHASE1","This is a Phase 1b study to assess the safety and tolerability of STI-1386, an oncolytic virus, in subjects with relapsed and refractory solid tumors (RRSTs).",[90,26,272,273,274],"Sarcoma","Hepatic Metastasis","Solid Tumor",[90,276,277],"solid tumor","hepatic metastasis","2023-04-10",{"date":280,"type":34},"2023-04-12",{"date":282,"type":22},"2023-08",{"date":284,"type":22},"2027-02",{"name":286,"class":156},"Sorrento Therapeutics, Inc."]